There are currently 1278 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Preoperative Weight Loss for Open Abdominal Wall Reconstruction
NCT05925959
Recruiting
The goal of this randomized controlled trial is to compare preoperative intensive weight management to upfront surgery in obese patients undergoing complex abdominal wall reconstruction. The main question is will abdominal wall specific quality of life (using the HerQLes survey) for the group undergoing upfront surgery be non-inferior compared to the group in the weight management program.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Cleveland Clinic Main Campus, Cleveland, Ohio
Conditions: Abdominal Wall Hernia
Register for Updates
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230
Recruiting
This is an open-label single arm study. All patients will receive the investigational agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma
Register for Updates
Consent for Use of Stored Patient Specimens for Future Testing
NCT00031408
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Cleveland Clinic (A2508), Cleveland, Ohio +1 locations
Conditions: HIV Infections
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Cleveland Clinic Children's, Cleveland, Ohio
Conditions: Neuroblastoma
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: MetroHealth Medical Center, Cleveland, Ohio +2 locations
Conditions: Ovarian Carcinoma
Register for Updates
Positive Processes and Transition to Health (PATH)
NCT06093906
Recruiting
The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Healt... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/17/2024
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease)
NCT04748861
Recruiting
The overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in e4 carriers. Successful translation and demonstration of the effectiveness of a scalable home-based exercise intervention capable of slowing or delaying disease onset will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
09/17/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: High Intensity Exercise, Normal Cognition, Exercise Intervention
Register for Updates
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
NCT05267262
Recruiting
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Gender:
ALL
Ages:
12 years and above
Trial Updated:
09/16/2024
Locations: Investigative site, Cleveland, Ohio
Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
NCT05980260
Recruiting
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS. Babies with NOWS often have tremors, a hard time sleeping, excessive crying, and trouble feeding. Some babies that have NOWS need medicine. Doctors have two ways of providing medicine that are widely used today: 1. Scheduled opioid taper approach. The baby gets medicine at regular times. As symptoms get better, the amount of medicine the baby gets decreases u... Read More
Gender:
ALL
Ages:
Between 1 hour and 48 hours
Trial Updated:
09/13/2024
Locations: Rainbow Babies and Children's Hospital, Cleveland, Ohio
Conditions: Neonatal Opiate Withdrawal Syndrome
Register for Updates
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239
Recruiting
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/13/2024
Locations: Recognify Research Site, Cleveland, Ohio
Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Register for Updates